- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
De Novo Membranous Nephropathy following Kidney Transplantation: A Consequence of Humoral Alloimmune Response? () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_1021;
Because of the persistence of severe proteinuria, patient was given 2 doses of rituximab 1 g each at 2 weeks apart with response awaited.Results Unlike recurrent MN, KTRs who develop de novo MN are younger, and test negative for anti-PLA2RA as in our case...The development of de novo MN in stem-cell transplant recipient with graft vs. host disease supports this hypothesis. Prognosis of de novo MN is less favorable than recurrent MN with higher risk for graft failure.
- |||||||||| Avastin (bevacizumab) / Roche
Case of Bevacizumab-induced Microangiopathy Masquerading as an Immune Complex Disorder () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_891;
The patient remained on maintenance pembrolizumab.Conclusion The evaluation of proteinuria in cancer patients receiving targeted therapies can present a diagnostic challenge. Although biopsy initially suggested an immune complex disorder requiring immunosuppression, the clinical picture better aligned with bevacizumab-associated TMA, confirmed by improvement after its discontinuation despite continuation of checkpoint inhibitor and lack of immunosuppression.
- |||||||||| hydralazine hydrochloride / Generic mfg.
Hydralazine-induced Lupus Syndrome (HILS) () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_704;
Losartan and empagliflozin were held outpatient...Given the absence of lupus nephritis in a recent biopsy & the unlikely involvement of kidneys in DIL, worsening kidney function was attributed to the progression of CKD.Results Hydralazine is a useful second-line antihypertensive but with serious adverse effects & is best used sparingly in the lowest effective doses and duration. Management of DIL includes discontinuing the causative agent and a brief course of steroids along with supportive measures as needed.Conclusion This case highlights the non-specific presentation in patients with HILS-related pericarditis and the need for constant vigilance
- |||||||||| Remicade (infliximab) / J&J
Focal Segmental Glomerulosclerosis in Behcets Disease () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_674;
Three months later the patient continues to be on infliximab, colchicine and losartan with a well-controlled BD stable renal function SC 1.1 mg/dl, Urine studies showing UACR 402 mg/g and no signs of hematuria.Results Determining whether the patient has secondary FSGS related to BD is challenging, as they are still on infliximab, which can both cause and treat FSGS. While only a few cases of renal involvement with FSGS in BD exist, we highlight the need to consider this association for early detection in patients with BD.Conclusion The patient's history of BD and treatment with immunosuppressive therapy highlights the complexity of diagnosing secondary FSGS, particularly when treatment regimens may influence renal pathology.
- |||||||||| Tarpeyo (budesonide) / Calliditas, Stada, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Recurrent IgA Nephropathy (IgAN) In A Transplant Recipient Managed With Targeted-Release of Budesonide and Dapagliflozin () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_642;
His creatinine has remained between 1.3-1.6mg/dL throughout his post transplant course.Results Traditional systemic corticosteroids are frequently limited by significant side effects, but can be mitigated by TR-budesonide, which targets Peyer's patches in the small intestine to reduce systemic exposure. This patient was successfully managed with TR-budesonide along with losartan and Dapa.Conclusion Tarpeyo is not currently approved for post-transplant IgAN, and its role in this context warrants further research.
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Chronic Thrombotic Microangiopathy: Conservative Management vs. Complement Inhibitor Therapy () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_621;
The patient began treatment with losartan and dapagliflozin, significantly improving his proteinuria. Over ten months, his kidney function has remained stable, suggesting conservative management may be an effective approach for treating chronic TMA of unknown cause compared to complement-targeted therapy.
- |||||||||| Rituxan (rituximab) / Roche
A Curious Case of Mercury-Induced Membranous Nephropathy () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_585;
This case underscores the importance of meticulous history-taking and interdisciplinary collaboration in managing rare toxin-induced kidney diseases. Early identification and targeted treatment can prevent serious complications.
- |||||||||| Rituxan (rituximab) / Roche
Renal Vein Thrombosis as Initial Presentation of PLA2R-Positive NSAID-Associated Membranous Nephropathy () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_516;
Anticoagulation, losartan, atorvastatin, dietary sodium restriction, and diuretics were initiated...The patient developed an allergic reaction during Rituximab infusion thus he was continued on cyclosporin...Although similar cases of MN have been reported with PLA2R-positivity, the target antigen is not known in most cases. A recent study suggests a novel protein proprotein convertase subtilisin/kexin type 6 (PCSK6) as the likely target antigen.
- |||||||||| losartan / Generic mfg.
Paging Nephrology: A Case of Page Kidney Caused by Spontaneous Rupture of a Hemorrhagic Cyst () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_471;
Labetalol was eventually replaced by Losartan 50 mg daily and blood pressures remained at goal...Rupture of renal cysts constitutes less than 1% of the published cases.Conclusion Renal cyst rupture can rarely result in subcapsular hematoma and page kidney. This entity causes hyperreninemic hypertension and is best treated with renin-angiotensin-aldosterone system inhibitors.
- |||||||||| losartan / Generic mfg.
Journal: A biomimetic dual-targeting nanomedicine for pancreatic cancer therapy. (Pubmed Central) - Mar 12, 2025
The strategy integrates iron carbonyl (FeCO), an anti-cancer agent, and losartan (Lo), a drug that degrades tumor matrix, into a biodegradable nanomaterial-mesoporous polydopamine (MPDA)...The (Lo + FeCO)@MPDA@CAFM-PTP nanomedicine demonstrated significant cytotoxicity against Panc-1 cells in vitro and effectively inhibited PC tumor growth in vivo. This innovative approach holds great promise for advancing pancreatic cancer treatment.
- |||||||||| losartan / Generic mfg., pioglitazone / Generic mfg.
Preclinical, Journal, IO biomarker: Pharmacologic and endotoxic reprogramming of renal vasodilatory, inflammatory, and apoptotic blemishes in weaning preeclamptic rats. (Pubmed Central) - Mar 9, 2025
Molecularly, the favorable effect of pharmacologic or endotoxic intervention was coupled with dampened tubular and glomerular expressions of inflammatory (toll-like receptor 4) and apoptotic signals (caspase-3). Our data unveil beneficial and possibly intensified conditioning effect for endotoxemia when combined with losartan or pioglitazone against preeclamptic renovascular dysfunction and inflammation.
- |||||||||| nitroprusside / Generic mfg., losartan / Generic mfg., atenolol / Generic mfg.
Trial completion date, Trial primary completion date: ANG-P: Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV (clinicaltrials.gov) - Mar 5, 2025
P2, N=134, Suspended,
Our data unveil beneficial and possibly intensified conditioning effect for endotoxemia when combined with losartan or pioglitazone against preeclamptic renovascular dysfunction and inflammation. Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
- |||||||||| nifedipine immediate release / Generic mfg., losartan / Generic mfg., lisinopril / Generic mfg.
Journal: Trends in antihypertensive use among privately insured hypertensive clients in Ghana. (Pubmed Central) - Feb 27, 2025
Most single medicine products was generic (76.5% in 2016; 79.9% in 2017 and 83.1% in 2018) whiles most fixed combination products were branded (73.0% in 2016; 89.7% in 2017 and 91.3% in 2018). The patterns of AHM use are clinically expected although the Ghana Standard Treatment guidelines are not directive about lines of treatment.
- |||||||||| Tekturna (aliskiren) / PDL
Clinical, Review, Journal: Renin inhibitors versus angiotensin receptor blockers for primary hypertension. (Pubmed Central) - Feb 27, 2025
The evidence was derived from short-term trials with a limited occurrence of morbidity outcomes, leaving any potential differences unknown. Larger RCTs of longer duration with a wider range of participants and a focus on cardiovascular outcomes are needed.
- |||||||||| losartan / Generic mfg., Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Angioedema Shortly After Adding Empagliflozin to Losartan. (Pubmed Central) - Feb 27, 2025
This finding suggests a possible cumulative adverse effect of such medications and should be considered when prescribing both histamine and bradykinin effectors. Additionally, this case report serves as an example of the importance of the early diagnosis and treatment of angioedema.
- |||||||||| losartan / Generic mfg.
Review, Journal: Resistant Hypertension: A Brief Review of Pathophysiology. (Pubmed Central) - Feb 25, 2025
His current medications currently include losartan 100 mg daily, hydrochlorothiazide 25 mg, and amlodipine 10 mg...Our understanding of the potential etiologies for this condition continues to evolve rapidly. We used a narrative review to explore four research areas in the pathophysiology of resistant hypertension (the sympathetic nervous system, aldosterone excess, endothelial dysfunction, and inflammation) and explore the novel therapies currently in development.
- |||||||||| losartan / Generic mfg.
Journal: Dietary phytosterol supplementation mitigates renal fibrosis via activating mitophagy and modulating the gut microbiota. (Pubmed Central) - Feb 24, 2025
The results indicated that high-dose PS are more effective than low-dose PS and Losartan potassium (LP) in reducing renal fibrosis, restoring function, and modulating oxidative stress and inflammation, with no significant differences between high-dose Stig and ?-Sito treatments...The present findings indicate that both Stig and ?-Sito activate mitophagy via the PINK1/Parkin pathway and modulate the gut microbiota, thereby alleviating renal fibrosis. The findings provide solid and significant implications for developing effective application of PS supplementation in the management of CKD, presenting novel concepts and approaches for research and clinical treatment.
- |||||||||| vadimezan (ASA404) / Antisoma
Journal, PD(L)-1 Biomarker, IO biomarker: A responsive cocktail nano-strategy breaking the immune excluded state enhances immunotherapy for triple negative breast cancer. (Pubmed Central) - Feb 20, 2025
The released Vad and damaged tumor DNA activated immune responses through the cGAS-STING pathway, while the elevated expression level of PD-L1 promoted the anti-tumor effect of BMS-1. Significant degradation of collagen fibers, restoration of immune effector cells, and lower tumor volume were observed in this integrated triple drug sequential therapy, which provides a promising prospect for TNBC treatment.
- |||||||||| losartan / Generic mfg.
Journal: Acute angiotensin receptor blockade and mnemonic discrimination in healthy participants. (Pubmed Central) - Feb 19, 2025
Consequently, targeting Ang II and AGTR1 could potentially emerge as a promising strategy for ESCC treatment. We demonstrate for the first time that losartan improves mnemonic discrimination in healthy individuals, suggesting that the RAS may influence pattern separation and anxiety.
- |||||||||| losartan / Generic mfg.
Journal: A voltammetric method for determining N-nitrosodimethylamine in losartan and olmesartan drugs. (Pubmed Central) - Feb 19, 2025
In addition, the proposed method uses instrumentation with low acquisition, operation, and maintenance costs and enables rapid determination of NDMA in sartan drugs with great sensitivity, reproducibility, and stability. As the proposed SWASV-BDDE-SAP method does not use chemical pretreatment of samples, such as derivatization and/or extraction with reagents and/or organic solvents, it can be considered a promising eco-friendly alternative for determining NDMA in routine analysis, thus contributing to green analytical chemistry.
- |||||||||| losartan / Generic mfg.
Review, Journal: The effectiveness of antioxidant agents in delaying progression of diabetic nephropathy: A systematic review of randomized controlled trials. (Pubmed Central) - Feb 18, 2025
Antioxidant agents that inhibit diabetic nephropathy can be classified as single antioxidants (silymarin, baicalin, epigallocatechin gallate, vitamin E, selenium, curcumin, ?-lipoic acid, and tocotrienol-rich vitamin E) and combined antioxidants (?-lipoic acid with vitamin B6, and resveratrol with losartan)...These agents contribute to reducing markers of oxidative stress and hyperglycemia-induced inflammation. Although several antioxidants play a role in reducing fibrosis markers, the effect does not appear to be statistically significant.
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Trial completion date, Trial primary completion date, Real-world evidence: Effect of Sacubitril/valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: a Real World Study (clinicaltrials.gov) - Feb 13, 2025
P=N/A, N=180, Recruiting,
More attention to sex differences in angiotensin receptor blockers' efficacy and underlying mechanisms of differences in response is needed. Trial completion date: Sep 2024 --> Jun 2027 | Trial primary completion date: Mar 2024 --> Dec 2026
- |||||||||| losartan / Generic mfg.
Journal, IO biomarker: Comparative Efficacy of ?-Carotene and Losartan Against Isoproterenol-Induced Cardiac Fibrosis: An Experimental and Computational Studies. (Pubmed Central) - Feb 10, 2025
?-carotene modulated IL-17, TNF, NF-kappa B, HIF-1, Sphingolipid, Relaxin, Adipocytokine, cAMP, Toll-like receptor, MAPK, PI3K-Akt, cGMP-PKG, VEGF, Ras, and PPAR signaling pathways. ?-carotene dose-dependently protects against ISO-induced CF in rats, with 40?mg/kg as an effective antifibrotic dose.
- |||||||||| losartan / Generic mfg.
Preclinical, Journal: The role of AT-1 antagonist on wound healing in rats with hypertension and diabetes. (Pubmed Central) - Feb 8, 2025
expression and classical SMAD signaling in hypertensive settings, its minor effect in diabetes conditions indicate the necessity of supplemental treatments that target mechanisms unique to hyperglycemia, such as glycation end products or oxidative stress inhibitors. To improve treatment outcomes for individuals with diabetes and hypertension comorbidities, future studies should investigate the combination of multi-pathway modulators.
- |||||||||| hydrochlorothiazide / Generic mfg., losartan / Generic mfg., rosuvastatin / Generic mfg.
Preclinical, Journal: Sustainability assessment of the micellar optimized HPLC method for concomitant quantification of a common triple regimen for cardiovascular disorders: application to marketed formulations and in vitro dissolution testing. (Pubmed Central) - Feb 6, 2025
It was also employed for monitoring their in vitro release pattern using two innovator tablet formulations, applying the USFDA guidelines. The applied procedure was evaluated and compared with previously published HPLC approaches using various metrics, including the Eco-Scale Scoring method (AES), the Green Analytical Procedure Index (GAPI), and the Analytical Greenness Calculator (AGREE) for greenness, the most current Blue Applicability Grade Index (BAGI) for blueness, and the more inclusive RGB 12 algorism for whiteness assessment.
- |||||||||| Trial completion date, Trial primary completion date: WARRIOR: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (clinicaltrials.gov) - Feb 6, 2025
P4, N=2476, Active, not recruiting,
The applied procedure was evaluated and compared with previously published HPLC approaches using various metrics, including the Eco-Scale Scoring method (AES), the Green Analytical Procedure Index (GAPI), and the Analytical Greenness Calculator (AGREE) for greenness, the most current Blue Applicability Grade Index (BAGI) for blueness, and the more inclusive RGB 12 algorism for whiteness assessment. Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Feb 2025
- |||||||||| losartan / Generic mfg.
Journal: Losartan in Situ Forming Gel as a New Treatment for Hypertrophic Scars. (Pubmed Central) - Feb 5, 2025
This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
- |||||||||| losartan / Generic mfg.
Journal: Restoring lung renin-angiotensin system balance through blood pressure control. (Pubmed Central) - Feb 5, 2025
Male spontaneously hypertensive rats (SHRs) were treated with either losartan or amlodipine, both of which effectively reduced BP...BP control with either an RAS inhibitor or a calcium channel blocker rebalances RAS in SHR lungs and alleviates inflammation. Furthermore, this study provides a mechanistic link between inflammatory lung diseases (such as COVID-19) and hypertension as a major risk factor.
- |||||||||| losartan / Generic mfg.
Review, Journal: Altered Balance between Vasoconstrictor and Vasodilator Systems in Experimental Hypertension. (Pubmed Central) - Feb 4, 2025
Central sympathoexcitation in this hypertensive model can be inhibited by lower losartan doses than peripheral angiotensin II-dependent vasoconstriction...Some abnormalities can be studied in blood vessels isolated from hypertensive rats but neither conduit arteries nor mesenteric resistance arteries represent the vascular beds decisive for the increased peripheral resistance and high BP. Keywords: Sympathetic vasoconstriction, NO-dependent vasodilatation, Calcium sensitization, Calcium influx, Arterial baroreflex, Spontaneously hypertensive rats, Salt hypertensive Dahl rats, Ren-2 transgenic rats, RAS blockade, SNS blockade, NOS inhibition, Endothelin, Vascular contraction and relaxation, Isolated conduit and resistance arteries, EDCF, PGI2, BKCa channels.
- |||||||||| losartan / Generic mfg.
Clinical, Journal: Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho: A Randomized Clinical Trial. (Pubmed Central) - Jan 29, 2025
P=N/A
Participants were randomized 2:2:1 to stepped monotherapy (amlodipine, 10 mg, with escalation to add hydrochlorothiazide if needed), 2-pill strategy (amlodipine, 5 mg; losartan, 25 mg), or 3-pill strategy (amlodipine, 2.5 mg; losartan, 12.5 mg; hydrochlorothiazide, 6.25 mg)...Wide CIs preclude the ability to rule out potentially clinically important effects of the additional pill strategies for hypertension control. ClinicalTrials.gov Identifier: NCT04129840.
- |||||||||| losartan / Generic mfg.
Journal: Evaluation effect of alginate hydrogel containing losartan on wound healing and gene expression. (Pubmed Central) - Jan 27, 2025
RT-PCR and immunohistochemistry analysis showed a decrease in expression level of TGF-?1 and VEGF in treatment groups. Histological analysis demonstrated that the alginate hydrogel containing Losartan can be effective in wound repair by decreasing the size of the scar and tissue remodeling, as evidenced by future in vivo studies.
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
The Head and the Heart: Ventricular Assist Device and Bipolar Disorder (Poster Hall) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_570;
After mood stabilization, he was discharged home 46 days post-VAD on lithium and olanzapine for BP-I, in addition to metoprolol, losartan, dapagliflozin, tadalafil, and anticoagulation with apixaban...After a 39 day admission, he was discharged home on aripiprazole and lorazepam...In the setting of good hemodynamic support, he is not listed for heart transplant while undergoing psychiatric medication optimization.Summary VAD support with concomitant BP-I disorder is a complex decision requiring multi-disciplinary collaboration, individualized care, and reliable mental health resources. We highlight an unmet need for optimal mental healthcare facilities for patients on VAD support.
|
